Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with ...

The AD risk factors/hits include high exposure to traffic-related air pollution (TRAP) and infections, as well as factors ...

An anti-Alzheimer's nasal spray that could delay the progress of the disease by years has been developed by scientists at ...

Alzheimer’s disease robs patients of so much more than their health. It can rewire their personalities and undermine a ...

And also we found the significant effects in terms of ADAS-Cog [Alzheimer's Disease Assessment Scale-Cognitive Subscale], ...

University of Washington-led research, published in 2023, discovered microglia in the brains of people with Alzheimer's ...

Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...

As we count down toward the December readout of Cassava Sciences’ simufilam Phase 3 clinical trial in Alzheimer’s disease, it ...

The EMA’s Committee for Medicinal Products for Human Use has issued a positive recommendation for Eisai and Biogen’s Leqembi ...

Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...

Researchers discovered that the enzyme TYK2 alters the tau protein, promoting its accumulation in the brain, a process linked ...